

CRO Communiqué
Keeping you informed about CRO progress
October 2013

Top Enrolling Physicians for September 2013

Physician	Patient Registrations	Treatment Credits	Control Credits	Total Credits
Dr. Carlson (Mercy Spfld)	7	1.3	5	6.3
Dr. Cunningham (Cox)	2	1	0.5	1.5
Dr. Ellis (Cox)	1	0	1	1
Dr. Graham (Phelps)	1	1	0	1
Dr. Gillett (Cox)	1	0	1	1
Dr. Hu (Mercy St. Louis)	2	1	0.5	1.5
Dr. Huq (Phelps- Mercy Rolla)	2	2	0	2
Dr. Oza (Good Samaritan)	1	0	0.5	0.5
Dr. Raju (Mercy Spfld)	1	0	1	1
Dr. Sleckman (Mercy St. Louis)	1	0	1	1
Dr. Verma (Cox)	1	1	0	1
Total	20	7.3	10.5	17.8

September has been a slow month for CRO enrollments. With one third of our grant year behind us we have earned 33.5 treatment credits and need to be at 43.3 to be on track to reach our grant year target of 130 treatment credits. We have earned 41.0 cancer control credits and need to have earned 46.7 control credits to be on track to meet this year cancer control target of 140. Attached is a “CRO’s Patient Registration Summary” which is updated monthly. I will begin attaching this to each Communiqué so we can all see where CRO is as a whole and where each site is in meeting our grant year accrual and credit goals.

Congratulations to Dr. Carlson

Congratulations Dr. Carlson! Dr. Carlson was recognized at the CCOP PI and Administrators meeting at NIH on September 20th with a Platinum Certificate of Excellence for his contributions to NCI clinical trials during grant year 2012-2013. Dr. Carlson had 80 enrollments resulting in 69.2 credits during grant year 2012 -2013.

NCORP Grant

No new news regarding the NCORP grant was announced at the PI and Administrators Conference at NIH on September 20th. It was reiterated the grant would be released this fall and would be due sometime in the winter.

Steering Committee

CRO’s fall Steering Committee meeting is being planned for Thursday, November 21st. Joseph M Anderson, MD FCAP from Redwood City, California will speak on Genomics in Cancer treatment the past, present and the future. More information will be coming.

Terry Fox Run

Special thanks to Terry Martin, a nurse anesthetist in Bolivar at CMH for putting together the first local Terry Fox Run to benefit CRO. The run was held on Saturday, September 28 in Bolivar. Terry, his family and friends worked hard and held a very organized event. The amount raised is undetermined at this time. Terry plans to make this an annual event.

New CRO Research Nurse

Janna Jones RN joined CRO as a research nurse on Friday, September 27, 2013. Janna is a Cox College BSN graduate. She previously worked in the ER at Cox. She will be joining our staff at Hulston Cancer Center. Welcome Janna!

New Studies Approved in September, 2013 Opened with Cox and Mercy IRBs

ECOG E1311 “A Randomized Phase II trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence”

RTOG 1306 “A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)

New Studies Approved in September, 2013 Opened with Mercy’s IRB

Alliance A011104 “Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer”

ECOG E3311 “Phase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer”

Studies Permanently Closed to Enrollment at Cox & Mercy in September 2013

GOG 0131H “A Phase II Evaluation of Ixabepilone in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus ”

GOG 0229K “A Phase II Evaluation of BIBF 1120 (IND #113086) in the Treatment of Recurrent or Persistent Endometrial Carcinoma ”

Studies Permanently Closed to Enrollment at Mercy in September 2013

E1A05 “Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade)-Lenalidomide (Revlimid)-Dexamethasone (VRD) versus Bortezomib (Velcade)-Dexamethasone (VD) for Patients With Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen”

SWOG S0927 “A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness in Women with Early Stage Breast Cancer, Phase III”